Edgewise Therapeutics, Inc. is an innovative biopharmaceutical company headquartered in Boulder, Colorado, specializing in the development of small molecule therapies targeted at musculoskeletal diseases. Leveraging its proprietary technology platform, Edgewise aims to provide precision medicine solutions that specifically address unmet medical needs in muscle disorders and bone injuries. With a promising pipeline of transformative therapies, the company is well-positioned to significantly enhance patient outcomes and redefine treatment standards in orthopedics, underscoring its commitment to advancing musculoskeletal health. Show more

Location: 1715 38TH STREET, BOULDER, CO, UNITED STATES, 80301, Boulder, CO, 80301, USA | Website: https://edgewisetx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

2.98B

52 Wk Range

$10.60 - $30.48

Previous Close

$28.78

Open

$28.58

Volume

839,946

Day Range

$27.67 - $28.64

Enterprise Value

2.421B

Cash

46.0M

Avg Qtr Burn

-34.78M

Insider Ownership

0.45%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Sevasemten (EDG-5506) Details Duchenne muscular dystrophy	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sevasemten (EDG-5506) Details Duchenne muscular dystrophy	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sevasemten (EDG-5506) Details Becker Muscular Dystrophy	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EDG-7500 Details Hypertrophic cardiomyopathies (HCM)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sevasemten (EDG-5506) Details Rare diseases, Limb-Girdle Muscular Dystrophy, McArdle disease	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sevasemten (EDG-5506) Details Becker Muscular Dystrophy	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sevasemten (EDG-5506) Details Becker Muscular Dystrophy	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EDG-15400 Details Heart Failure	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.